💊
Elrexfio
elranatamab
Mieloma múltiple
✅ Autorizado
✅
No hay alertas activas
Este medicamento no tiene escasez en curso, cartas de seguridad ni retiradas del mercado.
Para qué se utiliza
Elrexfio is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
⚠️ Seguridad del paciente
No
Página oficial de la EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/elrexfio